MétaCan
← all works

Antibody Characterization Report for Casein kinase II subunit alpha (CSNK2A1)

2024· article· en· 0 citations· W6892508065 on OpenAlex· 10.5281/zenodo.10818213

Why is this work in the frame?

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.

The three-model screen

all 1,000 screened works →

All three models called this out of scope.

stratum: aff_core · design weight: 5595.24 (the sample is stratified; any rate computed without the weight is wrong)
Claude Opus 4.8OUT
genre: empirical
about Canada: no
confidence: low

Antibody characterization report benchmarking commercial antibodies against CSNK2A1 with knockout-controlled protocols; the closest rubric anchor (Western blot protocol reproducibility) puts reagent-level validation OUT, yet such standardized characterization campaigns are explicitly reagent-reproducibility infrastructure, so this sits on the boundary.

GPT-5.6 (high)OUT
genre: empirical
about Canada: no
confidence: high

The study evaluates antibody performance in laboratory assays rather than research practice itself.

Grok 4.5OUT
genre: empirical
about Canada: no
confidence: medium

Lab reagent antibody characterization and assay performance; polysemy of validation, not study of research practice.

Abstract

A peer-reviewed antibody characterization article corresponding to this Zenodo preprint is openly available at F1000Research: https://doi.org/10.12688/f1000research.153243.2 This report presents a guide to selecting high-quality commercial antibodies against Casein kinase II subunit alpha (CSNK2A1) by Western blot, immunoprecipitation and immunofluorescence, using a standardized experimental protocol based on comparing read-outs in knockout cell lines and isogenic parental controls. This study was funded in part by the Simons Foundation Autism Research Initiative (SFARI), an organization that funds innovative research to enhance the understanding, diagnosis and treatment of autism spectrum disorders.

Stored with the screening record, where it is evidence for the labels above.

The record

Venue
Zenodo (CERN European Organization for Nuclear Research)
Topic
Prion Diseases and Protein Misfolding
Field
Biochemistry, Genetics and Molecular Biology
Canadian institutions
McGill UniversityMontreal Neurological Institute and Hospital
Funders
Keywords
ImmunoprecipitationAntibodyAlpha (finance)Casein kinase 2Protein subunitKinaseAutismCell cultureG alpha subunit
Has abstract in OpenAlex
yes